A Double-blind, Randomised, Placebo-controlled Study to Evaluate ToleroMune Ragweed in Ragweed Allergic Subjects Following Challenge With Ragweed Allergen in an Environmental Exposure Chamber.

Trial Profile

A Double-blind, Randomised, Placebo-controlled Study to Evaluate ToleroMune Ragweed in Ragweed Allergic Subjects Following Challenge With Ragweed Allergen in an Environmental Exposure Chamber.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2015

At a glance

  • Drugs Ragweed SPIRE (Primary)
  • Indications Allergic rhinoconjunctivitis; Ragweed pollen hypersensitivity
  • Focus Therapeutic Use
  • Sponsors Circassia
  • Most Recent Events

    • 16 May 2012 Status of the extension trial (NCT01448603) is completed as reported by ClinicalTrials.gov.
    • 16 May 2012 Status of the extension trial (NCT01448603) is completed as reported by ClinicalTrials.gov.
    • 16 May 2012 Actual patient number for the extension trial (NCT01448603) is 109, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top